Mode
Text Size
Log in / Sign up
N/A N=20

Mini Stem DEXA (Dual Energy X-ray Absorptiometry)

Osteoarthritis, Hip

Enrolled (actual)
20
Serious AEs
65.0%
Results posted
Mar 2020
Primary outcome: Primary: DEXA Analysis of BMD at Preoperative Visit — 0.8; 1.0; 1.6; 2.0 g/cm^2

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Smith & Nephew, Inc.
Primary completion
Apr 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
DEXA Analysis of BMD at Preoperative Visit
0.8; 1.0; 1.6; 2.0; 1.8; 1.3
PRIMARY
DEXA Analysis of BMD at 3 Months
0.8; 1.3; 2.1; 1.9; 1.9; 1.5
PRIMARY
DEXA Analysis of BMD at 6 Months
0.8; 1.3; 2.1; 1.9; 2.0; 1.6
PRIMARY
DEXA Analysis of BMD at 1 Year
0.8; 1.3; 2.1; 1.9; 1.9; 1.6
PRIMARY
DEXA Analysis of BMD at 2 Years
0.8; 1.3; 2.2; 1.9; 2.0; 1.6
SECONDARY
Baseline Harris Hip Score (HHS) at Preoperative Visit
17.0; 26.0; 3.8; 2.7; 49.5
SECONDARY
Harris Hip Score (HHS) at 3 Month Visit
37.5; 35.1; 4.0; 4.1; 82.6
SECONDARY
Harris Hip Score (HHS) at 6 Month Visit
40.8; 41.2; 4.0; 4.2; 90.1
SECONDARY
Harris Hip Score (HHS) at 1 Year Visit
38.0; 41.5; 4.0; 4.5; 87.3
SECONDARY
Harris Hip Score (HHS) at 2 Year Visit
40.7; 41.9; 4.0; 4.0; 90.6
SECONDARY
Harris Hip Score (HHS) at 5 Year Visit
43.6; 45.8; 4.0; 4.3; 97.7
SECONDARY
Hip Injury Osteoarthritis Outcome Score (HOOS) at Preoperative Visit
52.8; 49.1; 44.7; 22.1; 24.7
SECONDARY
Hip Injury Osteoarthritis Outcome Score (HOOS) at 3 Month Visit
83.0; 88.8; 84.8; 76.0; 73.1
SECONDARY
Hip Injury Osteoarthritis Outcome Score (HOOS) at 6 Month Visit
93.0; 94.2; 93.0; 80.4; 83.8
SECONDARY
Hip Injury Osteoarthritis Outcome Score (HOOS) at 1 Year Visit
90.0; 89.2; 87.8; 78.3; 82.4
SECONDARY
Hip Injury Osteoarthritis Outcome Score (HOOS) at 2 Year Visit
90.7; 92.5; 89.9; 81.6; 81.7
SECONDARY
Hip Injury Osteoarthritis Outcome Score (HOOS) at 5 Year Visit
96.5; 98.3; 97.2; 85.6; 95.8
SECONDARY
Radiographic Assessment at Preoperative Visit (Yes/No Components)
20; 0; 0; 20; 0; 20
SECONDARY
Radiographic Assessment at 3 Month Visit (Yes/No Components)
20; 0; 0; 20; 0; 20
SECONDARY
Radiographic Assessment at 1 Year Visit (Yes/No Components)
19; 1; 0; 20; 1; 19
SECONDARY
Radiographic Assessment at 5 Year Visit (Yes/No Components)
10; 0; 0; 10; 0; 10
SECONDARY
Radiographic Assessment at Discharge Visit
0; 40.9
SECONDARY
Radiographic Assessment at 3 Month Visit
0; 41.3
SECONDARY
Radiographic Assessment at 1 Year Visit
0; 41.3
SECONDARY
Radiographic Assessment at 5 Year Visit
10.5; 40.6
SECONDARY
Radiographic Assessment at Discharge Visit (Neutral/Valgus Component)
20; 0
SECONDARY
Radiographic Assessment at 3 Month Visit (Neutral/Valgus Component)
20; 0
SECONDARY
Radiographic Assessment at 1 Year Visit (Neutral/Valgus Component)
20; 0
SECONDARY
Radiographic Assessment at 5 Year Visit (Neutral/Valgus Component)
8; 2

Summary

The objective of this study is to evaluate the bone ingrowth after implantation of the study device. This study will also document any device-related surgical complications or adverse radiographic observations. Improvement in pain, function, and health economic data will be compared with improvements documented with other joint systems.

Eligibility Criteria

Inclusion Criteria

  • Patient has hip disease that requires a total hip arthroplasty.
  • Patient is willing to consent to participate in the study.
  • Patient plans to be available for the study duration.
  • Patient is in stable health and is free of or treated and stabilized for cardiac, pulmonary, hematological, or other conditions that would pose excessive operative risk.

Exclusion Criteria

  • Patient known to have insufficient bone stock.
  • Patient has had major non-arthroscopic surgery to the study hip.
  • Patient has physical, emotional or neurological conditions that would compromise the patient's compliance with postoperative rehabilitation and follow-up.
  • Patient has a known sensitivity to materials in the device.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01066936). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search